Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

NCT04412616 is registered in ClinicalTrials.gov with Changchun Intellicrown Pharmaceutical Co. LTD as lead sponsor.

NCT NCT04412616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04412616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Lead sponsor
Changchun Intellicrown Pharmaceutical Co. LTD
Phase
Phase 1
Overall status
Recruiting
Start date
September 1, 2020
Completion date
July 6, 2026
Enrollment
60 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced egfr positive solid tumor